A novel study on amyloid β peptide 40, 42 and 40/42 ratio in Saudi autistics

Behavioral and Brain Functions

Volumn 8, Issue , 2012, Pages

  Al Ayadhi, Laila Y ^a,b   Ben Bacha, Abir G ^a,b,c   Kotb, Malak ^c,d   El Ansary, Afaf K ^a,b,c  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b Autism Research and Treatment Center   (Saudi Arabia)

^c KING SAUD UNIVERSITY   (Saudi Arabia)

^d UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Amyloid beta; Autism; Brain influx; Cognitive disability; Neurotoxicity

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN (1 42); AMYLOID BETA-PROTEIN (1-42); BIOLOGICAL MARKER; PEPTIDE FRAGMENT;

ADOLESCENT; ARTICLE; AUTISM; BLOOD ANALYSIS; CHILD; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PLASMA; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; AREA UNDER THE CURVE; BLOOD; NEUROPSYCHOLOGICAL TEST; OXIDATIVE STRESS; PHYSIOLOGY; PSYCHOLOGICAL ASPECT; SAUDI ARABIA; STATISTICAL ANALYSIS;

ADOLESCENT; AMYLOID BETA-PEPTIDES; AREA UNDER CURVE; AUTISTIC DISORDER; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; DATA INTERPRETATION, STATISTICAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; OXIDATIVE STRESS; PEPTIDE FRAGMENTS; ROC CURVE; SAUDI ARABIA;

EID: 84857504095     PISSN: None     EISSN: 17449081     Source Type: Journal    
DOI: 10.1186/1744-9081-8-4     Document Type: Article

References (52)

1. World Health Organization The ICD-10 Classification of Mental and Behavioural Disorders (ICD-10), WHO, Geneva 1992, World Health Organization.
2. Rapin I. The autistic spectrum disorders. The New England Journal of Medicine 2002, 347:302-03. 10.1056/NEJMp020062, 12151466.
3. Fombonne E. Epidemiological trends in rates of autism. Molecular Psychiatry 2002, 7:S4-S6. 10.1038/sj.mp.4001162, 12142931.
4. King S, Laplante DP. The effects of prenatal maternal stress on children's cognitive development: Project Ice Storm. Stress 2005, 8:35-45. 10.1080/10253890500108391, 16019596.
5. King S, Mancini-Marie A, Brunet A, Walker E, Meaney MJ, Laplante DP. Prenatal maternal stress from a naturaldisaster predicts dermatoglyphic asymmetry in humans. Development and Psychopathology 2009, 21:343-53. 10.1017/S0954579409000364, 19338687.
6. Laplante DP, Barr RG, Brunet A, Galbaud du Fort G, Meaney ML, Saucier JF, et al. Stress during pregnancy affects general intellectual and language functioning in human toddlers. Pediatric Research 2004, 56:400-410. 10.1203/01.PDR.0000136281.34035.44, 15240860.
7. Laplante DP, Brunet A, Schmitz N, Ciampi A, King S. Project Ice Storm: prenatal maternal stress affects cognitive and linguistic functioning in 5 1/2-year-old children. Journal of the American Academy of Child & Adolescent Psychiatry 2008, 47:1063-72. 10.1097/CHI.0b013e31817eec80, 22243674.
8. Beversdorf DQ, Manning SE, Hillier A, Anderson SL, Nordgren RE, Walters SE, et al. Timing of prenatal stressors and autism. Journal of Autism and Developmental Disorders 2005, 35:471-8. 10.1007/s10803-005-5037-8, 16134032.
9. Kinney DK, Miller AM, Crowley DJ, Huang E, Gerber E. Autism prevalence following prenatal exposure to hurricanes and tropical storms in Louisiana. Journal of Autism and Developmental Disorders 2008, 38:481-8. 10.1007/s10803-007-0414-0, 17619130.
10. Kinney DK, Munir KM, Crowley DJ, Miller AM. Prenatal stress and risk for autism. Neuroscience & Biobehavioral Reviews 2008, 32:1519-32. 10.1016/j.neubiorev.2008.06.004, 22268092.
11. Gutmann B, Hutter-Paier B, Skofitsch G, Windisch M, Gmeinbauer R. In vitro models of brain ischemia: the peptidergic drug cerebrolysin protects cultured chick cortical neurons from cell death. Neurotoxicology Research 2002, 4:59-65.
12. Sogut S, Zorogǧlu SS, Ozyurt H, Yilmaz HR, Ozugǧurlu F, Sivasli E, et al. Changes innitric oxide levels and antioxidant enzyme activities may have a role in the pathophysiological mechanisms involved in autism. Clinica Chimica Acta 2003, 331:111-117.
13. S S, Zoroglu F, Armutcu S, Ozen A, Gurel E, Sivasli O, Yetkin I. Meram, Increased oxidative stress and altered activities of erythrocyte free radical scavenging enzymes in autism. European Archives of Psychiatry and Clinical Neuroscience 2004, 254:143-147.
14. Chauhan A, Chauhan V, Brown WT, Cohen I. Oxidative stress in autism: increased lipid peroxidation and reduced serum levels of ceruloplasmin and transferring--the antioxidant proteins. Life Science 2004, 75:2539-49.
15. Geier DA, Kern JK, Garver CR, Adams JB, Audhya T, et al. Biomarkers of environmental toxicity and susceptibility in autism. Journal of Neurological Science 2009, 280:101-108.
16. Al-Gadani Y, El-Ansary A, Attas O, Al-Ayadhi L. Metabolic biomarkers related to oxidative stress and antioxidant status in Saudi autistic children. Clinical Biochemistry 2009, 42:1032-1040. 10.1016/j.clinbiochem.2009.03.011, 19306862.
17. Katzman R, Saitoh T. Advances in Alzheimer's disease. FASEB J 1991, 4:278-286.
18. Jarrett JT, Berger EP, Lansbury PT. The C-terminus of the beta protein is critical in amyloidogenesis. Annals of the New York Academy of Sciences 1993, 695:144-8. 10.1111/j.1749-6632.1993.tb23043.x, 8239273.
19. Weller RO, Massey A, Newman TA, Hutchings M, Kuo YM, Roher AE. Cerebral amyloid angiopathy: amyloid beta accumulates in putative interstitial fluid drainage pathways in Alzheimer's disease. American Journal of Pathology 1998, 153:725-33. 10.1016/S0002-9440(10)65616-7, 1853019, 9736023.
20. Bruce-Keller AJ, Begley JG, Fu W, Butterfield DA, Bredesen DE, Hutchins JB, Hensley K, Mattson MP. Bc1-2 protects isolatedplasma, and mitochondrial membranes against lipid peroxidation induced by hydrogen peroxide, and amyloid-peptide. Journal of Neurochemistry 1998, 70:31-9.
21. Butterfield DA, Drake J, Pocernich C, Castegna A. Evidence of oxidative damage in Alzheimer's disease brain: central role of amyloid beta-peptide. Trends in Molecular Medicine 2001, 7:548-54. 10.1016/S1471-4914(01)02173-6, 11733217.
22. Reich EE, Markesbery WR, Roberts LJ, Swift LL, Morrow JD, Montine TJ. Brain regional quantification of F-ring and D-/Ering isoprostanes and neuroprostanes in Alzheimer's disease. American Journal of Patholology 2001, 158:293-7.
23. Butterfield DA, Lauderback CM. Lipid peroxidation and protein oxidation in Alzheimer's disease brain: potential causes and consequences involving amyloid β-peptide-associated free radical oxidative stress. Free Radical Biology & Medicine 2002, 32:1050-60. 10.1016/S0891-5849(02)00794-3, 22263861.
24. Varadarajan S, Yatin S, Aksenova M, Butterfield DA. Review: Alzheimer's amyloidβ-peptide-associated free radical oxidative stress, and neurotoxicity. Journal of Structural Biology 2000, 130:184-208. 10.1006/jsbi.2000.4274, 10940225.
25. Giedraitis V, Sundelöf J, Irizarry MC, Gårevik N, Bradley H, Wahlund LO, et al. The normal equilibrium between CSF and plasma amyloid beta levels is disrupted in Alzheimer's disease. Neuroscience Letters 2007, 427:127-131. 10.1016/j.neulet.2007.09.023, 17936506.
26. Sambamurti K, Greigh NH, Lahiri DK. Advances in the cellular and molecular biology of the beta-amyloid protein in Alzheimer's disease. Neuromolecular Medicine 2002, 1:1-31. 10.1385/NMM:1:1:1, 12025813.
27. Matsuoka Y, Saito M, LaFrancois J, Gaynor K, Olm V, Wang L, et al. Noveltherapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to beta-amyloid. Journal of Neuroscience 2003, 23:29-33.
28. Jaeger LB, Dohgu S, Sultana R, Lynch JL, Owen JB, Erickson MA, et al. Lipopolysaccharide alters the blood-brain barrier transport of amyloid β protein: A mechanism for inflammation in the progression of Alzheimer's disease. Brain Behavior and Immunity 2009, 23:507-17.
29. Oliveira G, Diogo L, Grazina M, Garcia P, Ataíde A, Marques C, et al. Mitochondrial dysfunction in autism spectrum disorders: a population-based study. Developmental Medicine & Child Neurology 2005, 47:185-9. 10.1017/S0012162205000332, 22267598.
30. Al-Mosalem OA, El-Ansary A, Attas O, Al-Ayadhi L. Metabolic biomarkers related to energy metabolism in Saudi autistic children. Clinical Biochemistry 2009, 42:949-957. 10.1016/j.clinbiochem.2009.04.006, 19376103.
31. El-Ansary A, Al-Daihan S, Al-Dbass A, Al-Ayadhi L. Measurement of selected ions related to oxidative stress and energy metabolism in Saudi autistic children. Clinical Biochemistry 2010, 43:63-70. 10.1016/j.clinbiochem.2009.09.008, 19781542.
32. Palmieri L, Persico AM. Mitochondrial dysfunction in autism spectrum disorders: Cause or effect?. Biochimica et Biophysica Acta 2010, 1797:1130-37. 10.1016/j.bbabio.2010.04.018, 20441769.
33. Sokol DK, Chen D, Farlow MR, Dunn DW, Maloney B, Zimmer JA, et al. High levels of Alzheimer beta-amyloid precursor protein (APP) in children with severely autistic behavior and aggression. J child Neurol 2006, 21:444-9.
34. Bailey AR, Giunta BN, Obregon D, Nikolic WV, Tian J, Sanberg CD, et al. Peripheral biomarkers in Autism: secreted amyloid precursor protein-α as a probable key player in early diagnosis. International Journal of Clinical and Experimental Medicine 2008, 1:338-44. 2596331, 19079679.
35. Opazo C, Huang X, Cherny RA, Moir RD, Roher AE, White AR, et al. Metalloenzyme-like activity of Alzheimer's disease beta-amyloid. Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H2O2, Journal of Biological Chemistry 2002, 277:40302-8.
36. Fang CL, Wu WH, Liu Q, Sun X, Ma Y, Li YM. Dual functions of β-amyloid oligomer and fibril in Cu(II)-induced H2O2 production. Regulatory Peptides 2010, 163:1-6. 10.1016/j.regpep.2010.05.001, 20478342.
37. Atwood CS, Obrenovicha ME, Liua T, hana HC, Perrya G, Smith MA, et al. Amyloid-β: a chameleon walking in two worlds: a review of the trophic and toxic properties of amyloid-β Martins. Brain Research Reviews 2003, 43:1-16. 10.1016/S0165-0173(03)00174-7, 14499458.
38. Amstad P, Peskin A, Shah G, Mirault ME, Moret R, Zbinden I. The balance between Cu, Zn-superoxide dismutase and catalase affects the sensitivity of mouse epidermal cells to oxidative stress. Biochemistry 1991, 30:9305-9313. 10.1021/bi00102a024, 1654093.
39. Zhong S, Wu K, Black IB, Schaar DG. Characterization of the genomic structure of the mouse APLP1 gene. Genomics 1996, 32:159-162. 10.1006/geno.1996.0096, 8786110.
40. Sato K, Akaike T, Kohno M, Ando M, Maeda H. Hydroxyl radical production by H2O2 plus Cu,Zn-superoxide dismutase reflects the activity of free copper released from the damaged enzyme. Journal of Biological Chemistry 1992, 267:25371-77.
41. Pflanzner T, Janko MC, André-Dohmen B, Reuss S, Weggen S, Roebroek AJM, et al. LRP1 mediates bidirectional transcytosis of amyloid-β across the blood-brain barrier. Neurobiology of Aging Corrected Proof, Available online 13 July 2010.
42. Deane R, Wu Z, Sagare A, Davis J, Yan SD, Hamm K, Xu F, Parisi M, LaRue B, Hu HW, Spijkers P, Guo H, Song X, Lenting PJ, Van Nostrand WE, Zlokovic BV. LRP/Amyloid β-Peptide Interaction Mediates Differential Brain Efflux of Aβ Isoforms. 2004, 43:333-44.
43. Gu H, Wei X, Monnot AD, Fontanilla CV, Behl M, Farlow MR, et al. Lead exposure increases levels of β-amyloid in the brain and CSF and inhibits LRP1 expression in APP transgenic mice. Neuroscience Letters 2011, 490:16-20. 10.1016/j.neulet.2010.12.017, 3026879, 21167913.
44. Fryer JD, Simmons K, Parsadanian M, Bales KR, Paul SM, Sullivan PM, et al. Human apolipoprotein E4 alters the amyloid-beta 40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model. J Neurosci 2005, 25:2803-2810. 10.1523/JNEUROSCI.5170-04.2005, 15772340.
45. Herzig MC, Winkler DT, Burgermeister P, Pfeifer M, Kohler E, Schmidt SD, et al. Abeta is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis. Nat Neurosci 2004, 7:954-960. 10.1038/nn1302, 15311281.
46. Frackowiak J, Mazur-Kolecka B, Kuchna I, Nowicki K, Brown WT, Wegiel J. Accumulation of Amyloid-Beta Peptide Species In Four Brain Structures In Children with Autism. International Meeting for Autism Research 2011, Manchester Grand Hyatt San Diego, California.
47. Calderón-Garciduẽnas L, Solt A, Henríquez-Roldán C, Torres-Jardón R, Nuse B, Herritt L, et al. Long-term air pollution exposure is associated with neuroinflammation, an altered innate immune response, disruption of the blood-brain-barrier, ultrafine particle deposition, and accumulation of amyloid beta 42 and alpha synuclein in children and young adults. Toxicol Pathol 2008, 36:289-310. 10.1177/0192623307313011, 18349428.
48. Garciduẽnas LC, D'Angiulli A, Kulesza RJ, Torres-Jardón R, Osnaya N, Romero L, et al. Air pollution is associated with brainstem auditory nuclei pathology and delayed brainstem auditory evoked potentials. Int J Devl Neuroscience 2011, 29:365-375.
49. Lahiri DK, Maloney B. The ''LEARn" (Latent Early-life Associated Regulation) model integrates environmental risk factors and the developmental basis of Alzheimer's disease, and proposes remedial steps. Experimental Gerontology 2010, 45:291-296. 10.1016/j.exger.2010.01.001, 2881328, 20064601.
50. Lahiri DK, Maloney B, Zawia NH. The LEARn model: an epigenetic explanation for idiopathic neurobiological diseases. Molecular Psychiatry 2009, 14:992-1003. 10.1038/mp.2009.82, 19851280.
51. Lahiri DK, Zawia NH, Greig NH, Sambamurti K, Maloney B. Early-life events may trigger biochemical pathways for Alzheimer's disease: the ''LEARn" model. Biogerontology 2008, 9:375-379. 10.1007/s10522-008-9162-6, 18668339.
52. Deth R, Muratore C, Benzecry J, Power-Charnitsky VA, Waly M. How environmental and genetic factors combine to cause autism: A redox/methylation hypothesis. NeuroToxicology 2008, 29:190-201. 10.1016/j.neuro.2007.09.010, 18031821.